U.S.-India Business Council: India to Scrutinize Drug Licenses

Mar 08, 2016

Reuters

According to a Reuters article, the U.S.-India Business Council (USIBC) claimed that India will not grant licenses allowing local firms to override patents and make cheap copies of drugs by Western drugmakers.

The comments were given in a submission by the USIBC to the U.S. Trade Representative (USTR), which is reviewing global intellectual property laws for an annual report identifying trade barriers to U.S. companies, the story said.

The USTR says the country's patent laws unfairly favor local drug makers. Read the full article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments